Skip to main content

Retinoids

  • Reference work entry
  • First Online:
Cancer Therapeutic Targets

Abstract

Retinoids are natural and synthetic derivatives of vitamin A. The anticancer properties of retinoids have been extensively investigated in the preclinical, epidemiological and clinical settings. The primary targets of the retinoids are retinoid receptors. Retinoid receptors are ligand-activated transcription factors, members of the steroid nuclear receptor family. Retinoid receptors are deregulated in a number of malignant diseases including the fusion of RARα with PML in acute promyelocytic leukemia (APL) and the repression of RARβ in lung and head and neck cancers. In some cases, pharmacologic doses of retinoids can overcome these cancer specific defects in retinoid signaling. High-doses of retinoids induce differentiation and apoptosis of tumor cells, which is related to their physiologic effects in regulating embryonic development and maturation during hematopoiesis and in diverse epithelial tissues. Retinoid receptors have been cancer therapy targets for more than 30 years, and there are a number of FDA-approved retinoid-based therapies, the most impactful is the standard of care of all-trans-retinoic acid induced differentiation therapy of APL. Clinical evaluation of retinoids, especially newer synthetic retinoids in combination with molecular targeted and epigenetic therapy remains an active area of investigation in oncology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 649.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 949.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Dezube BJ, Pantanowitz L, Aboulafia DM. Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment. AIDS Read. 2004;14:236–8.

    PubMed  Google Scholar 

  • Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E. Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol. 2005;23:8757–64.

    Article  CAS  PubMed  Google Scholar 

  • Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, Nugent WC, Hermann T, Negro-Vilar A, Rigas JR, Dmitrovsky E. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res. 2007;13:1794–800.

    Article  CAS  PubMed  Google Scholar 

  • Duester G. Retinoic acid synthesis and signaling during early organogenesis. Cell. 2008;134:921–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene. 2003;22:7305–15.

    Article  CAS  PubMed  Google Scholar 

  • Freemantle SJ, Liu X, Feng Q, Galimberti F, Blumen S, Sekula D, Kitareewan S, Dragnev KH, Dmitrovsky E. Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem. 2007;102:869–77.

    Article  CAS  PubMed  Google Scholar 

  • Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, De Lera AR, Lotan R, Mangelsdorf DJ, Gronemeyer H. International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol Rev. 2006a;58:712–25.

    Article  CAS  PubMed  Google Scholar 

  • Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, De Lera AR, Lotan R, Mangelsdorf DJ, Gronemeyer H. International Union of Pharmacology. LXIII. Retinoic X receptors. Pharmacol Rev. 2006b;58:760–72.

    Article  PubMed  Google Scholar 

  • Goodman GE, Thornquist MD, Balmes J, Cullen MR, Meyskens Jr FL, Omenn GS, Valanis B, Williams Jr JH. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst. 2004;96:1743–50.

    Article  CAS  PubMed  Google Scholar 

  • Grimwade D, Mistry AR, Solomon E, Guidez F. Acute promyelocytic leukemia: a paradigm for differentiation therapy. Cancer Treat Res. 2010;145:219–35.

    Article  CAS  PubMed  Google Scholar 

  • Klass CM, Shin DM. Current status and further development of chemoprevention in head and neck cancer. Curr Cancer Drug Targets. 2007;7:623–32.

    Article  CAS  PubMed  Google Scholar 

  • Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs. 2010;70:273–86.

    Article  CAS  PubMed  Google Scholar 

  • Lippman SM, Lotan R. Advances in the development of retinoids as chemoprevention agents. J Nutr. 2000;130:479S–82.

    CAS  PubMed  Google Scholar 

  • Lippman SM, Heyman RA, Kurie JM, Benner SE, Hong WK. Retinoids and chemoprevention: clinical and basic studies. J Cell Biochem Suppl. 1995;22:1–10.

    Article  CAS  PubMed  Google Scholar 

  • Matthay KM, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. Long-term results from children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children’s Oncology Group study. J Clin Oncol. 2009;27:1007–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Moon RC, Mehta RG, Rao KVN. Retinoids and cancer in experimental animals. In: Sporn MB, Roberts AB, Goodman DS, editors. The retinoids: biology, chemistry, and medicine. New York: Raven Press; 1994. p. 573–95.

    Google Scholar 

  • Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood. 2009;113:3655–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • O’Malley BW, Qin J, Lanz RB. Cracking the coregulator codes. Curr Opin Cell Biol. 2008;20:310–5.

    Article  PubMed  PubMed Central  Google Scholar 

  • Petrie K, Zelent A, Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol. 2009;16:84–91.

    Article  CAS  PubMed  Google Scholar 

  • Rochette-Egly C, Germain P. Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs). Nucl Recept Signal. 2009;7, e005.

    PubMed  PubMed Central  Google Scholar 

  • Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110:2302–8.

    Article  CAS  PubMed  Google Scholar 

  • Spinella MJ, Kerley JS, White KA, Curtin JC. Retinoid target gene activation during induced tumor cell differentiation: human embryonal carcinoma as a model. J Nutr. 2003;133:273S–6.

    PubMed  Google Scholar 

  • Sporn MB, Roberts AB, Goodman DS. The retinoids: biology, chemistry and medicine. 2nd ed. New York: Raven Press; 1994.

    Google Scholar 

  • Stapnes C, Gjertsen BT, Reikvam H, Bruserud Ø. Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opin Invest Drugs. 2009;18:433–55.

    Article  CAS  Google Scholar 

  • Tanaka T, De Luca LM. Therapeutic potential of “rexinoids” in cancer prevention and treatment. Cancer Res. 2009;69:4945–7.

    Article  CAS  PubMed  Google Scholar 

  • Tang X-H, Gudas LJ. Retinoids, retinoic acid receptors and cancer. Annu Rev Pathol Mech Dis. 2011;6:345–64.

    Article  CAS  Google Scholar 

  • Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, Miceli R, DiMauro MG, Costa A, Marubini E, Sporn MB, DePalo G. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancers. Ann Oncol. 2006;17:1065–71.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ethan Dmitrovsky .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media New York

About this entry

Cite this entry

Dmitrovsky, E., Spinella, M. (2017). Retinoids. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0717-2_15

Download citation

Publish with us

Policies and ethics